表紙
市場調査レポート

非ホジキンリンパ腫:世界の治験動向

Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016

発行 GlobalData 商品コード 227700
出版日 ページ情報 英文 2277 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
非ホジキンリンパ腫:世界の治験動向 Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016
出版日: 2016年05月31日 ページ情報: 英文 2277 Pages
概要

当レポートでは、非ホジキンリンパ腫に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主要国における治験の状況、地域・フェーズ(相)別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における非ホジキンリンパ腫の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における非ホジキンリンパ腫の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

非ホジキンリンパ腫治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3417CTIDB

GlobalData's clinical trial report, "Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Non-Hodgkin Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Hodgkin Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Non-Hodgkin Lymphoma Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Non-Hodgkin Lymphoma
      • May 12, 2016: Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology
      • Apr 28, 2016: Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
      • Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016
      • Apr 19, 2016: Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting
      • Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
      • Apr 18, 2016: Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016
      • Apr 18, 2016: Seattle Genetics Highlights Data on ADCETRIS at the American Association for Cancer Research Annual Meeting
      • Apr 18, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 Demonstrating Differentiated Effects on T-Cells
      • Mar 18, 2016: Asana BioSciences, to Provide Update on ASN003, a Novel BRAF/PI3K Kinase Inhibitor, at the 14th International Congress on Targeted Anticancer Therapies
      • Mar 17, 2016: Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program
      • Mar 17, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research Annual Meeting
      • Mar 16, 2016: Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research
      • Mar 09, 2016: Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top